A cost-benefit analysis of gown use in controlling vancomycin-resistant Enterococcus transmission:: Is it worth the price?

被引:52
作者
Puzniak, LA
Gillespie, KN
Leet, T
Kollef, M
Mundy, LM
机构
[1] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA
[2] St Louis Univ, Sch Publ Hlth, Dept Community Hlth, St Louis, MO 63103 USA
[3] St Louis Univ, Sch Publ Hlth, Dept Hlth Management & Policy, St Louis, MO 63103 USA
关键词
D O I
10.1086/502416
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
OBJECTIVE: To determine the net benefit and costs associated with gown use in preventing transmission of vancomycin-resistant Enterococcus (VRE). DESIGN: A cost-benefit analysis measuring the net benefit of gowns was performed. Benefits, defined as averted costs from reduced VRE colonization and infection, were estimated using a matched cohort study. Data sources included a step-down cost allocation system, hospital informatics, and microbiology databases. SETTING: The medical intensive care unit (MICU) at Barnes-Jewish Hospital, St. Louis, Missouri. PATIENTS: Patients admitted to the MICU for more than 24 hours from July 1, 1997, to December:31, 1999. INTERVENTIONS: Alternating periods when all health-care workers and visitors were required to wear gowns and gloves versus gloves alone on entry to the rooms of patients colonized or infected with VRE. RESULTS: On base-case analysis, 58 VRE cases were averted with gown use during 18 months. The annual net benefit of the gown policy was $419,346 and the cost per case averted of VRE was $1,897. The analysis was most sensitive to the level of VRE transmission. CONCLUSIONS: Infection control policies (eg, gown use) initially increase the cost of health services delivery. However, such policies can be cost saving by averting nosocomial infections and the associated costs of treatment. The cost savings to the hospital plus the benefits to patients and their families of avoiding nosocomial infections make effective infection control policies a good investment.
引用
收藏
页码:418 / 424
页数:7
相关论文
共 53 条
[1]  
[Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P565
[2]   The effectiveness of cost-effectiveness analysis in containing costs [J].
Azimi, NA ;
Welch, HG .
JOURNAL OF GENERAL INTERNAL MEDICINE, 1998, 13 (10) :664-669
[3]   A REAPPRAISAL OF HEPATITIS-B VIRUS VACCINATION STRATEGIES USING COST-EFFECTIVENESS ANALYSIS [J].
BLOOM, BS ;
HILLMAN, AL ;
FENDRICK, AM ;
SCHWARTZ, JS .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (04) :298-306
[4]  
Bonten MJM, 1996, INFECT CONT HOSP EP, V17, P193
[5]   The role of "colonization pressure" in the spread of vancomycin-resistant enterococci - An important infection control variable [J].
Bonten, MJM ;
Slaughter, S ;
Ambergen, AW ;
Hayden, MK ;
van Voorhis, J ;
Nathan, C ;
Weinstein, RA .
ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (10) :1127-1132
[6]   OUTBREAK OF MULTIDRUG-RESISTANT ENTEROCOCCUS-FAECIUM WITH TRANSFERABLE VANB CLASS VANCOMYCIN RESISTANCE [J].
BOYCE, JM ;
OPAL, SM ;
CHOW, JW ;
ZERVOS, MJ ;
POTTERBYNOE, G ;
SHERMAN, CB ;
ROMULO, RLC ;
FORTNA, S ;
MEDEIROS, AA .
JOURNAL OF CLINICAL MICROBIOLOGY, 1994, 32 (05) :1148-1153
[7]  
Boyce JM, 1996, INFECT CONT HOSP EP, V17, P256
[8]   A hospital epidemic of vancomycin-resistant Enterococcus:: Risk factors and control [J].
Byers, KE ;
Anglim, AM ;
Anneski, CJ ;
Germanson, TP ;
Gold, HS ;
Durbin, LJ ;
Simonton, BM ;
Farr, BM .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2001, 22 (03) :140-147
[9]   Health and economic outcomes of vancomycin-resistant enterococci [J].
Carmeli, Y ;
Eliopoulos, G ;
Mozaffari, E ;
Samore, M .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (19) :2223-2228
[10]  
*CDCP, 2002, MMWR MORB MORTAL WKL, V51, P902